The TROPiCS-02 trial demonstrated an OS benefit of 3.2 months from Sacituzumab govitecan-hziy compared to TPC (single agent chemotherapy, median OS:14.4 months versus 11.2 months) for patients with metastatic HR+ and HER2-negative breast tumors [1,6]. The gene discussed is ERBB2; the disease is breast neoplasm.